{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 38,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a process-flow layout to show the trial design and its downstream impact (publications and Phase 3).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/12",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.35,
        "y": 0.79
      },
      "kind": "callout",
      "text": "Results of the VIRO-15 Phase 2 Trial were published in JAMA Oncology (Link)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a733f940-5b95-4705-80d5-dc8df559e792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.43,
        "w": 0.48,
        "x": 0.28,
        "y": 0.29
      },
      "kind": "diagram",
      "text": "Interventional Single Group Assignment n=27; Design: Olvi-Vec in combination with chemotherapy...; Endpoints: Primary: Median progression-free survival (mPFS)...",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "769fe6ae-9bf3-4ade-a9e3-c8a31229878b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.24,
        "x": 0.02,
        "y": 0.435
      },
      "kind": "list",
      "text": "High-grade serous, endometrioid or clear-cell ovarian cancer which includes: platinum-resistant or PRROC with at least two prior lines of therapy; ECOG Performance status is at 0 or 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5fbe2d0-69a3-47ba-b9dc-60eb31119401",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.27,
        "x": 0.715,
        "y": 0.25
      },
      "kind": "list",
      "text": "1. 2020 Digital Annual Meeting of International Gynecologic Cancer Society (Oral Plenary Session); 2. JAMA Oncology (Selected for Journal podcast series interview)",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f14d41e-eaf1-4070-a7e4-87d95123764e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.27,
        "x": 0.715,
        "y": 0.605
      },
      "kind": "paragraph",
      "text": "Ongoing Pivotal Phase 3 for the treatment of PRROC patients, using the same Experimental Arm treatment regimen",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "090cbdb7-71e3-46af-8e10-a3c7ea6f5f6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.14
      },
      "kind": "title",
      "text": "Olvi-Vec Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1d77cae-cb61-4137-86b0-6946e1d27d36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Completed Phase 2 Tested Olvi-Vec Immunochemotherapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9211bd84-67c8-468f-a606-5f39661d0a60",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "83be791e-933d-4f18-b9f2-62f978b0e45c",
      "evidence": "The title of this slide is an action title, describing the results of a clinical trial.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "b2065266-2330-4c07-9c75-430b381405ae",
      "evidence": "The slide uses a left-to-right flow to describe the clinical trial lifecycle.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 12,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "111fab6b-cd67-49dd-a414-d1390f2ab5d3",
      "evidence": "The presentation presents data on the clinical reversal of platinum resistance and refractoriness among patients with PRROC, highlighting the potential benefits of using Olvi-Vec.",
      "position": 0,
      "objective": "To highlight the cost of not using Olvi-Vec, specifically the limited treatment options for patients with platinum-resistant or platinum-refractory ovarian cancer",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}